Retin-A (Tretinoin) Use During Pregnancy

Critical Distinction: Topical vs. Oral Retinoids

The American College of Hematology recommends that oral tretinoin (ATRA) is highly teratogenic and absolutely contraindicated in the first trimester, causing retinoic acid embryopathy with craniofacial abnormalities, cardiac defects, thymic abnormalities, and CNS malformations, with a high strength of evidence 1, 3, 4
The National Comprehensive Cancer Network notes that topical tretinoin (Retin-A) has minimal systemic absorption and substantially lower teratogenic potential, with a moderate strength of evidence 1, 2

The European LeukemiaNet guidelines emphasize that oral ATRA is highly teratogenic in the context of acute promyelocytic leukemia, but this does not apply to topical dermatologic use, with a high strength of evidence 1, 7, 8

For women currently pregnant with topical tretinoin exposure, discontinue topical tretinoin immediately upon pregnancy recognition, with a moderate strength of evidence 5, 6
For women planning pregnancy, discontinue topical tretinoin at least 1 month before attempting conception, with a moderate strength of evidence 5, 6
For women requiring systemic retinoid therapy, oral tretinoin (ATRA) is absolutely contraindicated in the first trimester, but can be used in the second and third trimesters with multidisciplinary involvement, with a high strength of evidence 1, 7, 8

The National Comprehensive Cancer Network guidelines note that oral tretinoin is contraindicated during pregnancy for cancer treatment, but this does not extrapolate to topical formulations, with a moderate strength of evidence 2